Sonnet BioTherapeutics Holdings, Inc. short interest in 2021
In 2021, Sonnet BioTherapeutics Holdings, Inc.'s disclosed short interest ran from 5.16% of shares outstanding on 15 Jan 2021 to 0.57% on 31 Dec 2021, a change of -4.59 percentage points. The year's high was 20.50% on 15 Sep 2021 and its low 0.57% on 31 Dec 2021, averaging 6.63% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.18 days on 13 Aug 2021. Full history: Sonnet BioTherapeutics Holdings, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2021 in figures
- Start of year
- 5.16% (15 Jan 2021)
- End of year
- 0.57% (31 Dec 2021)
- Change
- -4.59 pp
- High
- 20.50% (15 Sep 2021)
- Low
- 0.57% (31 Dec 2021)
- Average
- 6.63%
- Highest days to cover
- 7.18 (13 Aug 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 5.16% | 1.48 | |
| 29 Jan 2021 | 5.00% | 1.00 | |
| 12 Feb 2021 | 4.26% | 1.00 | |
| 26 Feb 2021 | 3.40% | 1.00 | 10-Q filed, results (8-K) |
| 15 Mar 2021 | 4.91% | 1.00 | |
| 31 Mar 2021 | 2.24% | 1.00 | |
| 15 Apr 2021 | 1.96% | 1.09 | |
| 30 Apr 2021 | 1.71% | 1.00 | |
| 14 May 2021 | 4.07% | 1.00 | |
| 28 May 2021 | 2.48% | 1.00 | 10-Q filed, results (8-K) |
| 15 Jun 2021 | 3.59% | 1.00 | |
| 30 Jun 2021 | 6.70% | 1.68 | |
| 15 Jul 2021 | 9.96% | 2.86 | |
| 30 Jul 2021 | 15.31% | 3.89 | |
| 13 Aug 2021 | 13.33% | 7.18 | |
| 31 Aug 2021 | 19.46% | 1.00 | 10-Q filed, results (8-K) |
| 15 Sep 2021 | 20.50% | 1.00 | |
| 15 Dec 2021 | 1.38% | 1.00 | |
| 31 Dec 2021 | 0.57% | 1.00 | 10-K filed, results (8-K) |
See also: Sonnet BioTherapeutics Holdings, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.